Goldman Sachs Downgrades Jazz Pharmaceuticals (JAZZ) to Neutral

December 16, 2013 7:07 AM EST
Get Alerts JAZZ Hot Sheet
Price: $102.30 +0.49%

Rating Summary:
    27 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade JAZZ Now!
Join SI Premium – FREE
Goldman Sachs downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Buy to Neutral with a price target of $123.00 (from $105.00).

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $114.53 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

Goldman Sachs

Add Your Comment